Skip to main content
. 2017 Dec 20;162(2):611–621. doi: 10.1093/toxsci/kfx283

Figure 1.

Figure 1.

Pharmacokinetic analyses of AEOL10150. The concentration of AEOL10150 in plasma at 1, 3, 6, 12, 24, and 48 h by s.c. (A) or by i.v (B) and in hippocampus at 48 h (C) after AEOL10150 5 mg/kg, s.c. or i.v. with saline + standard therapy or DFP + standard therapy treatment (n = 3/group).